Dental Care Clinics in Amityville, NY Accepting Medicare
6 Dental Care Clinics found. Showing 1 - 6
 Scott Levitz Dds Pc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 151 Merrick Rd, Amityville, NY 11701 Phone: 631-691-8220 |
Complete Health Dental Of Amityville Dentist Medicare: Not Enrolled in Medicare Practice Location: 151 Merrick Rd, Amityville, NY 11701 Phone: 631-691-8220 Fax: 631-691-8224 |
Sasha Cekada Dds P C Dentist Medicare: Not Enrolled in Medicare Practice Location: 193 Broadway, Suite 2, Amityville, NY 11701 Phone: 631-598-2940 Fax: 631-598-8287 |
Geetha Balamurugan,d.d.s.,p.c. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 116 Broadway, Amityville, NY 11701 Phone: 631-264-2610 Fax: 631-264-2612 |
Amityville Orthodontics P.c. Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 18 Broadway, Amityville, NY 11701 Phone: 631-201-8100 |
South Amityville Dental Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 200 Albany Ave, Amityville, NY 11701 Phone: 631-842-0300 |
News Archive
MGH study shows the importance of fatty acid balance in chronic disease
Using novel transgenic mouse models they developed, Massachusetts General Hospital investigators have provided new evidence that it is the ratio of omega-6 and omega-3 fatty acids, rather than the total amount of them, that influences risk of developing chronic disease.
Study demonstrates that Parkinson's patients are more creative than their healthy peers
Prof. Rivka Inzelberg of Tel Aviv University's Sackler Faculty of Medicine and the Sagol Neuroscience Center at Sheba Medical Center, Tel Hashomer, documented the exceptional creativity of Parkinson's patients two years ago in a review for Behavioral Neuroscience. Since then, she has conducted the first empirical study to verify a link between Parkinson's disease and artistic inclination.
Linagliptin mono- and combination therapy improves blood glucose control
Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.
Researchers reveal first three-dimensional molecular map of protein linked to many cancers
Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular 'map' of a protein that has been pinpointed as a driver of many types of cancers.
› Verified 2 days ago